Quantcast

Latest Interferon beta-1a Stories

2014-09-09 16:25:56

- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression, and 'no evident disease activity' (NEDA) measure for interferon beta-1a SC vs. interferon beta-1a IM ROCKLAND, Mass., Sept. 9, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the division's multiple sclerosis...

2014-09-09 04:21:06

~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and Nervous System Repair BOSTON, Sept. 9, 2014 /PRNewswire/ -- On September 10-13 at the Hynes Convention Center in Boston, MA, ACTRIMS-ECTRIMS will host their joint triennial international meeting - MSBoston 2014, with over 8,000 participant from leading organizations in Europe, North America and...

2014-09-02 08:31:32

ROCKLAND, Mass., Sept. 2, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products. http://photos.prnewswire.com/prnvar/20140902/141784 Bringing more than 20 years of experience leading global and...

2014-08-12 16:27:31

DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Biological drugs are typically derived from living cells and are used in the treatment and prevention of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders....

2014-07-22 12:27:43

Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few...

2014-06-26 12:29:42

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Moduleshttp://www.reportbuyer.com/pharma_healthcare/diseases/multiple_sclerosis_kol_insight_consensus_outlook_modules.html IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market...

2014-05-28 08:33:20

ROCKLAND, Mass., May 28, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Rebif(®) (interferon beta-1a) data will be presented at the 2014 Cooperative Meeting of CMSC (Consortium of Multiple Sclerosis Centers) and ACTRIMS (Americas Committee on Research & Treatment in Multiple Sclerosis), taking place from May 28 - 31, in Dallas, TX. http://photos.prnewswire.com/prnvar/20121220/SF32295LOGO-b Data from 11 study assessments will...

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-04-25 08:28:05

ROCKLAND, Mass., April 25, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66(th )Annual Meeting, taking place from April 26 - May 3, in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20121220/SF32295LOGO-b Data from 14 study assessments presented by EMD Serono or its affiliate, Merck Serono, the...

2014-02-27 08:29:40

MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of (Pr)LEMTRADA(TM) (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.